Restrict the role of pharmacy benefit managers in order to lower drug costs.

Lower drug costs by restricting the role that Pharmacy Benefit Managers (PBM’s) play

Commits to limiting PBM influence to reduce drug prices.

The American Affordability Agenda | Seth Moulton for Massachusetts
campaign · campaign_site · model gpt-5.4-mini

Axios reported that the Department of Labor issued a PBM transparency rule requiring semiannual disclosures of what PBMs earn for negotiating drug prices, but the rule "stops short" of limiting spread pricing or requiring all rebates to be passed through.

This is a concrete federal step toward restricting PBMs and lowering drug costs, but it is narrower than a full role restriction.

partial same_term

PBMs hit by Trump transparency rule
secondary · model gpt-5.4-mini · confidence 78%

The article states that in February 2026 Congress passed additional PBM restrictions as part of the Consolidated Appropriations Act of 2026, requiring PBMs to pass through 100 percent of rebates to employer health plans, add transparency and data reporting, and shift Medicare reimbursement toward a flat-fee model starting in 2028.

This is the strongest concrete sign that the policy goal was substantively delivered in Moulton's term, even though the source is a secondary summary rather than the underlying bill text.

delivered same_term

Pharmacy benefit management
secondary · model gpt-5.4-mini · confidence 63%